Integrated Microfluidic Platform for Point-of-Care Serodiagnostics

用于护理点血清诊断的集成微流控平台

• 批准号: 8513911
• 负责人: Abraham P. Lee
• 金额: $ 30万
• 依托单位: IMMPORT THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8513911
• 关键词: Acoustics; Address; Air; Antibiotics; Antibodies; Antigens; Automobile Driving; Bartonella henselae; Bedside Testings; Biological Assay; Biological Warfare; Borrelia burgdorferi; Brucella melitensis; Brucellosis; Burkholderia pseudomallei; Chlamydia; Clinical; Collaborations; Collection; Communicable Diseases; Country; Coxiella burnetii; DNA; Data; Dengue; Detection; Development; Devices; Diagnosis; Diagnostic; Disasters; Disease; Disease Outbreaks; Electronics; Emergency Situation; Enzyme Immunoassay; Enzyme-Linked Immunosorbent Assay; Equipment; Evaluation; Francisella tularensis; Funding; Future; Generations; Genomics; Hand; Healthcare; Hepatitis B Virus; Hour; Housing; Human Papillomavirus; Immune response; Immunoassay; Immunodominant Antigens; Immunological Diagnosis; Individual; Infection; Infectious Agent; Laboratories; Lateral; Liquid substance; Location; Lyme Disease; Malaria; Melioidosis; Methods; Microarray Analysis; Microfabrication; Microfluidics; Miniaturization; Modeling; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Natural Disasters; Orientia tsutsugamushi; Patients; Phase; Plasmodium falciparum; Plastics; Population; Power Sources; Poxviridae; Production; Protein Microchips; Proteins; Proteome; Pump; Reagent; Research Infrastructure; Rickettsia rickettsii; Role; Salmonella enterica; Sampling; Scanning; Sensitivity and Specificity; Serological; Serum; Simplexvirus; Smallpox; Source; Speed; Spottings; Staging; Symptoms; System; Technical Expertise; Techniques; Technology; Testing; Time; Toxoplasma gondii; Training; Transducers; Tularemia; United States National Institutes of Health; Vaccines; Validation; West Nile virus; base; clinical Diagnosis; cost; cost effective; design; emergency service responder; experience; improved; instrumentation; meetings; micro-total analysis system; microorganism; microsystems; nano; new technology; novel; novel diagnostics; pathogen; point of care; point-of-care diagnostics; portability; prevent; prototype; rapid detection; rural area; screening; tool; trend

DESCRIPTION (provided by applicant): We aim to develop a fully integrated microfluidic immunodiagnostic platform utilizing a novel air-liquid cavity acoustic transducer (ALCAT) technology pioneered in the lab of Dr Abe Lee. The diagnosis platform is based on the well-established clinical diagnostic tool, the enzyme immunoassay (eg ELISA). ELISAs are an integral platform for clinical diagnosis because they are rapid, robust, and provide results that are highly sensitive and specific. Additionally, ELISAs rely on the inherent humoral immune response of the host to produce antibodies indicative of pathological status. In this proposal, we will form a strategic partnership of expertise in protein microarrays (Antigen Discovery, Inc. and Dr Phil Felgner) and in microfluidics (Dr Abe Lee) to develop a point-of-care diagnostic system consisting of a cost-effective disposable microfluidic plastic chip and a portable analyzer that can be driven by a mobile computing device for rapid serological evaluation of Melioidosis. By synergistically incorporating novel ALCAT-based approaches into these arrays we will have the versatility and power to reduce enzymatic development times, limit production costs, and fully integrate all components into a disposable assay. From previous NIH/NIAID funding we have discovered serodiagnostic antigens for 12 NIAID priority agents (Brucella melitensis, Francisella tularensis, Burkholderia pseudomallei, Coxiella burnetii, Salmonella enterica typhi, Rickettsia rickettsii, Orientia tsutsugamushi, Toxoplasma gondii, M. tuberculosis, variola major related pox viruses, Dengue, and West Nile). We have also identified serodiagnostic antigens for non-biodefense targets including: Bartonella henselae, Borrelia burgdorferi, Hepatitis B Virus, Chlamydia, Plasmodium falciparum, Human papillomavirus, and Herpes simplex virus. This approach will leverage our existing content of serodiagnostic antigens (and appropriate banked sera collection) to produce a multiplex device that will contain multiple antigens from numerous pathogens and enable clinicians to determine which pathogen an individual was exposed to. We believe the platform takes advantage of this wealth of content, and marries it to a versatile ALCAT-based microfluidics approach to produce a true lab-on-a- chip tool that is equipment free, technical expertise unrestricted, and useful for both developed and undeveloped countries. This approach produces a an immensely powerful diagnostic platform that will compliment current assays, provide diagnosis for a broad range of diseases, and is capable of utilizing additional enzyme immunoassay-based content. This proposal is an effective integration of emerging microarray technologies and will set the stage for future serological detection systems.

描述（由申请人提供）：我们旨在利用在Abe Lee博士的实验室中开发的新型空气腔声音传感器（Alcat）技术，开发完全集成的微流体免疫诊断平台。诊断平台基于公认的临床诊断工具，即免疫测定酶（例如ELISA）。 ELISA是临床诊断的组成平台，因为它们快速，稳健，并且提供了高度敏感和特异性的结果。此外，ELISA依赖于宿主的固有的体液免疫反应来产生指示病理状态的抗体。在这项建议中，我们将建立蛋白质微阵列（Antigen Discovery，Inc。和Phil Felgner博士）和微流体（Abe Lee博士）的战略合作伙伴关系，以开发一种由易于效率的可提供的微型塑料CHIP和便携式分析仪进行的，可以驱动一台移动式计算式的服务点诊断系统。通过协同将基于ALCAT的新型方法结合到这些阵列中，我们将具有减少酶促开发时间，限制生产成本并将所有组件完全集成到一次性测定中的多功能性和功能。 From previous NIH/NIAID funding we have discovered serodiagnostic antigens for 12 NIAID priority agents (Brucella melitensis, Francisella tularensis, Burkholderia pseudomallei, Coxiella burnetii, Salmonella enterica typhi, Rickettsia rickettsii, Orientia tsutsugamushi, Toxoplasma gondii,结核病。我们还确定了非双二重态靶标的血清诊断抗原，包括：Bartonella Henselae，Borrelia burgdorferi，乙型肝炎病毒，衣原体，恶性疟原虫，人类乳头状病毒和疱疹病毒。这种方法将利用我们现有的血清诊断抗原（和适当的储备血清收集）的含量来生产一种多重设备，该设备将包含来自众多病原体的多种抗原，并使临床医生能够确定个人暴露于哪些病原体。我们认为该平台利用了这些丰富的内容，并将其与一种多功能的基于Alcat的微流体方法结合使用，以生产一种真正的实验室，该工具是无设备，技术专业知识无限制且对发达国家和未开发国家都有用的。这种方法产生了一个功能强大的诊断平台，可以补充当前测定法，为各种疾病提供诊断，并能够利用其他基于酶的免疫测定内容。该建议是新兴微阵列技术的有效整合，并将为未来的血清学检测系统奠定基础。

项目成果

LCAT pump optimization for an integrated microfluidic droplet generator.

针对集成微流体液滴发生器的 LCAT 泵优化。

• 发表时间: 2015
• 期刊: Microfluidics and nanofluidics
• 影响因子: 2.8
• 作者: Fang,Wei-Feng;Lee,AbrahamP
• 通讯作者: Lee,AbrahamP